Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows in line with its trailing trend
Q3 FY2026 revenue of $3.44B rose 11.8% year over year, ahead of the +10.8% change in trailing-twelve-month revenue. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 21 analysts of $13.26B (+9.8%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $3.44B+3.2% QoQ
- Last fiscal yearDec 2025
- $12.07B+9.6% YoY
- LTMSep 2026
- $12.99B+10.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.8% | +8.3% | -3.5 pp |
| 1 year | +9.6% | +9.8% | +0.2 pp |
| 3-year CAGR | +10.6% | +11.1% | +0.5 pp |
| 5-year CAGR | +11.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 12.07B USD
- Year-over-year change
- +9.6%
- 4-year CAGR
- +12.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.07B | +9.6% |
| FY2024 | 2024-12-31 | 11.02B | +11.7% |
| FY2023 | 2023-12-31 | 9.87B | +10.5% |
| FY2022 | 2022-12-31 | 8.93B | +17.9% |
| FY2021 | 2021-12-31 | 7.57B | — |
Revenue vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Sep 2026 revenue of $12.99B is the 2nd highest of the 11 companies compared; the peer median is $836.42M.
- Its year-over-year change of +10.8% is the 7th highest of 11, against a peer median of +29.2%.
- Over three fiscal years its annual growth of +10.6% compares with a peer median of +32.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.03T | +33102.2% | +15.4% | |
| LTM Sep 2026 | $12.99B | +10.8% | +10.6% | |
| LTM Jun 2026 | $4.8B | +95.1% | +53.0% | |
| LTM Mar 2026 | $2.18B | -2.2% | +33.1% | |
| LTM Jun 2026 | $1.01B | -42.8% | +35.3% | |
| LTM Sep 2026 | $959.76M | -0.7% | +17.1% | |
| LTM Jun 2026 | $713.07M | +202.4% | +86.3% | |
| LTM Mar 2026 | $669.43M | +13.3% | +22.8% | |
| LTM Jun 2026 | $156.04M | +158.9% | +31.9% | |
| LTM Mar 2026 | $66.09M | +45.0% | +9.1% | |
| LTM Sep 2026 | $25.17M | -33.1% | +100.4% | |
| Peer median (excluding VRTX) | $836.42M | +29.2% | +32.5% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57B | 8.93B | 9.87B | 11.02B | 12.07B |
| Cost of Revenue | 904.2M | 1.08B | 1.26B | 1.53B | 1.81B |
| Gross Profit | 6.67B | 7.85B | 8.61B | 9.49B | 10.27B |
| Gross Margin | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% |
| Research & Development | 3.05B | 2.66B | 3.16B | 3.63B | 3.75B |
| Selling, General & Admin | 840.1M | 944.7M | 1.14B | 1.46B | 1.75B |
| Operating Expenses | 3.89B | 3.54B | 4.78B | 9.72B | 5.51B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| EBITDA | 2.92B | 4.44B | 4.61B | 486.3M | 4.87B |
| EBITDA Margin | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% |
| Operating Income | 2.78B | 4.31B | 3.83B | (232.9M) | 4.76B |
| Operating Margin | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% |
| Interest Income | 4.9M | 144.6M | 614.7M | 598.1M | 490.9M |
| Interest Expense | 61.5M | 54.8M | 44.1M | 30.6M | 13.3M |
| Other Income / Expenses | (51.7M) | (75M) | 547.8M | 481.4M | (117.5M) |
| Income Before Tax | 2.73B | 4.23B | 4.38B | 248.5M | 4.64B |
| Pre-Tax Margin | 36.0% | 47.4% | 44.4% | 2.3% | 38.5% |
| Income Tax Expense | 388.3M | 910.4M | 760.2M | 784.1M | 690M |
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Net Margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% |
| EPS (Basic) | 9.09 | 12.97 | 14.05 | (2.08) | 15.46 |
| EPS (Diluted) | 9.01 | 12.82 | 13.89 | (2.08) | 15.32 |
| Weighted Avg Shares | 257.7M | 256.1M | 257.7M | 257.5M | 255.7M |
| Weighted Avg Shares (Diluted) | 259.9M | 259.1M | 260.5M | 257.9M | 258M |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.